Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide effects on beta-cell function after secondary failure to oral agents in type 2 diabetes
2011-003335-63Phase 2Completed
- Sponsor
- Azienda Ospedaliero-Universitaria Pisana
- Start
- Jun 2012
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of liraglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Azienda Ospedaliero-Universitaria Pisana. Primary endpoint: Beta-cell glucose sensitivity. Started Jun 2012; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2011-003335-63.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003335-63.